Formation and Business of the Company	12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Formation and Business of the Company	Formation and Business of the Company The Company Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong and Japan. Liquidity and Going Concern The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $521.6 million as of December 31, 2025. During the years ended December 31, 2025 and December 31, 2024, the Company used $32.4 million and $31.5 million of cash in its operating activities, respectively. As of December 31, 2025, the Company had cash and cash equivalents of $69.8 million. Historically, the Company’s activities have been financed through the sale of its products, the sale of equity securities, and debt financing arrangements. The Company’s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash and cash equivalents, and the refinancing of debt described in Note 14, “Subsequent Events⸺Perceptive Credit Agreement”, will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these consolidated financial statements.

Formation and Business of the Company

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong and Japan.

Liquidity and Going Concern

The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $521.6 million as of December 31, 2025. During the years ended December 31, 2025 and December 31, 2024, the Company used $32.4 million and $31.5 million of cash in its operating activities, respectively. As of December 31, 2025, the Company had cash and cash equivalents of $69.8 million. Historically, the Company’s activities have been financed through the sale of its products, the sale of equity securities, and debt financing arrangements.

The Company’s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash and cash equivalents, and the refinancing of debt described in Note 14, “Subsequent Events⸺Perceptive Credit Agreement”, will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these consolidated financial statements.